Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of intravitreal bevacizumab versus ranibizumab in macular degeneration and other exudative macular diseases
2013-000133-12Phase 4Terminated
- Sponsor
- Azienda Ospedaliera Universitaria Integrata Verona
- Start
- Jun 2014
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial in age-related macular degeneration (AMD) comparing Bevacizumab intravitreal injection with Ranibizumab intravitreal injection (2 arms). Primary endpoint: Composite safety endpoint. Started Jun 2014; status: terminated.
02
Drugs
bevacizumabranibizumab
03
Conditions
age-related macular degeneration (AMD)
Beyond the preview
Go deeper on 2013-000133-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-000133-12.